Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 4, 2012, Pages 558-560

  Payen, Marie Christine ^a   De Wit, S ^a   Martin, C ^a   Sergysels, R ^a   Muylle, I ^a   Van Laethem, Y ^a   Clumeck, N ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Carbapenems plus clavulanate; Extensively drug resistant tuberculosis; Salvage therapy

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CYCLOSERINE; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HOME CARE; HUMAN; LUNG RESECTION; LUNG TUBERCULOSIS; MALE; PRIORITY JOURNAL; RELAPSE; SALVAGE THERAPY; SPUTUM CULTURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; CLAVULANIC ACID; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; THIENAMYCINS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84858638496     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0414     Document Type: Article

References (10)

1. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
2. Gandhi N R, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-1843.
3. Nadler J P, Berger J, Nord J A, et al. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991; 99: 1025-1026.
4. Yew W W, Wong C F, Lee J, et al. Do beta-lactam-beta-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? Tubercle Lung Dis 1995; 76: 90-92.
5. Hugonnet J E, Blanchard J S. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 2007; 46: 11198-12004.
6. Hugonnet J E, Tremblay L W, Boshoff H I, Barry C E III, Blanchard J S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323: 1215-1218.
7. Payen M C, Martin C, Antoine-Moussiaux T, et al. Four cases of XDR-tuberculosis treated with meropenem-clavulanate. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12-15 September 2010, Boston, MA, USA [Slide session L1-517]. Washington DC, USA: American Society for Microbiology, 2010. http://www.abstractsonline.com/Plan/ ViewAbstract.aspx?sKey=7189a738-03a3-41e0-8ee5-cf36269b5766&cKey= aceae86c-c8ae-4d8e-968e-d2dd95abed53&mKey=%7B93AEED6A-54D4-4EF6-99BD- A9B3CE9FACD9%7D Accessed December 2011.
8. Jacobson K R, Tierney D B, Jeon C Y, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
9. Migliori G B, Eker B, Richardson M D, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
10. Veziris N, Truffot C, Mainardi J L, Jarlier V. Activity of carbapenems combined with clavulanate in murine tuberculosis. Antimicrob Agents Chemother 2011; 55: 2597-2600.